… explored, but no current phase III data show superiority of an … An association between
estrogens and lung cancer risk first … when an increase in lung cancer mortality was observed in …

… -molecule tyrosine kinase inhibitor erlotinib may be considered … consisting of the oral agents
erlotinib and sorafenib, an … activity than erlotinib alone to merit a subsequent phase III trial. …

… or gefitinib as treatment of advanced or metastatic stage IIIB … Cancer classification. The
following study selection criteria were used: phase II and phase III randomized studies of erlotinib …

… IUNO was a randomized, double-blind, multicenter, placebo-controlled phase III trial of
maintenance erlotinib versus erlotinib at the time of disease progression in patients with …

… The ATLAS trial was a phase III study comparing maintenance erlotinib plus bevacizumab
versus bevacizumab alone in patients with NSCLC without progressive disease after four …

… Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small
cell lung cancer: the Tarceva Lung Cancer … TRIBUTE: a phase III trial of erlotinib …

… FASTACT-2 is a randomized, placebo-controlled, phase 3 study in first-line advanced
NSCLC, which met its primary endpoint of significantly prolonged PFS with intercalated erlotinib …

… In the placebo-controlled phase III SATURN study, maintenance erlotinib after first-line
chemotherapy demonstrated significantly prolonged progression-free survival (PFS) and overall …

… in three common lung cancer symptoms, showed that patients receiving … Phase III
randomized trials with erlotinib in advanced non-small cell lung cancer and pancreatic cancer …

… -naive patients with unresectable stage III or IV NSCLC; age … erlotinib combined with GC
was not significantly inferior to GC alone, with the exception of increased incidences of grade 3…